home
Bringing New Horizons to Therapy
Investor Information
Event: March 30, 2010 EDAP TMS is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers.
Recent Releases
Mar 10, 2010
EDAP Announces Webcast and Conference Call of Fourth Quarter and Full Year 2009 Results
Mar 9, 2010
EDAP Receives Japanese Approval for Sonolith I-Sys
Events & Presentations
Nov 17, 2009 at 8:30 AM ET
EDAP Third Quarter 2009 Results Conference Call
Sep 1, 2009 at 8:30 AM ET
EDAP Second Quarter 2009 Results Conference Call
IR Contact
Stock Information
|
NASDAQ : EDAP Last Price : 3.04 Change : 0.22  7.805%Day High : 3.23 Day Low : 2.75 Year High : 5.95 Year Low : 0.96 Volume : 271,600 |